Şunu aradınız:: prolactinoma (İngilizce - Maltaca)

veralipride treatment is contra-indicated in patients with prolactin- dependent tumours such as pituitary gland prolactinoma and breast cancer.
trattament b’ veralipride huwa kontra- indikat f’ pazjenti b’ tumuri dipendenti fuq il- prolaktin bħalma huma prolaktinoma tal- glandola pitwitarja u l- kanċer tas- sider.

-recommendations of medical breast monitoring and intermittent schedule (20 days followed by a 10- day period of non-treatment) to reduce the risk of hyperprolactinemia, aimed to improve the breast safety (however, it is unknown whether this measure has any effect on the observed adverse event pattern related to hyperprolactinemia like breast enlargement, galactorrhoea and risk for patients with prolactin-dependent tumours such as pituitary gland prolactinoma and breast cancer).
- rakkomandazzjonijiet ta ’ monitoraġġ mediku tas- sider u skeda intermittenti (20 jum segwiti minn perijodu ta ’ 10 ijiem mingħajr trattament) biex inaqqsu r- riskju ta ’ iperprolaktinimja, immirati biex itejbu s- sigurtà tas- sider (madankollu, mhux magħruf jekk din il- miżura għandhiex xi effett fuq il - forma ta ’ episodju avvers osservat relatat ma ’ l- iperprolaktinimja bħal tkabbir tas- sider, galaktorreja u riskju għal pazjenti b’ tumuri dipendenti fuq il- prolaktin bħal ma huma prolaktinoma tal- glandola pitwitarja u kanċer tas- sider).